Dabrafenib, another BRAF inhibitor, resulted in a case of PRES with Bálint’s syndrome—a triad of optic ataxia, oculomotor apraxia, and simultanagnosia [69]. The gene discussed is BRAF; the disease is Oculomotor apraxia.